<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04128384</url>
  </required_header>
  <id_info>
    <org_study_id>HOM-TAVI</org_study_id>
    <nct_id>NCT04128384</nct_id>
  </id_info>
  <brief_title>Infranodal Conduction Time During TAVR as Predictor of HAVB</brief_title>
  <acronym>HOM-TAVI</acronym>
  <official_title>Changes in Infranodal Conduction Times and New Onset Left Bundle Branch Block: Possible Predictors for High-grade AV Block Following Transcatheter Aortic Valve Replacement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Saarland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Saarland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Consecutive patients with high grade aortic stenosis undergoing transcatheter aortic valve
      replacement (TAVR) with a self-expanding valve (Medtronic CoreValve Evolut R® or Edwards
      Sapien S3®) without pre-existing pacemaker devices are eligible for inclusion. During the
      TAVR procedure, an electrophysiologic study including measurements of infranodal conduction
      times (HV-interval before and after valve implantation) will be performed. Electrocardiograms
      before TAVR, before discharge, after 30 days and after 12 months will be analyzed regarding
      new onset LBB and the occurrence of high-degree AV block (HAVB) .
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 21, 2018</start_date>
  <completion_date type="Anticipated">January 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>High-degree AV block</measure>
    <time_frame>24 months</time_frame>
    <description>Occurence of high-degree AV block necessitating a pacemaker implantation during follow up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Persistence of left bundle-branch block</measure>
    <time_frame>24 months</time_frame>
    <description>Persistence of new onset left bundle branch-block following TAVR procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences between implanted valve types on ifranodal conduction</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Severe Aortic Valve Stenosis</condition>
  <condition>High-degree AV Block</condition>
  <condition>Left Bundle-Branch Block</condition>
  <arm_group>
    <arm_group_label>EPS arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Limited electrophysiologic study including measurements of HV- and AH-intervals pre- and post-TAVR</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Limited electrophysiologic study including measurements of HV- and AH-intervals pre- and post-TAVR</intervention_name>
    <description>For the purpose of obtaining intracardiac measurements, the quadripolar diagnostic catheter used as temporary pacemaker wire (5F, Woven, Boston Scientific) during TAVR was retracted from the apex and positioned at the His bundle to measure HV- and AH-intervals.</description>
    <arm_group_label>EPS arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Indication for TAVR according to current guidelines

          2. Written informed consent

        Exclusion Criteria:

        1. Pre-existent intracardiac device as pacemaker, implanted cardioverter defibrillator or
        CRT-P/CRT-D device
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Ukena, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum des Saarlandes, Homburg/Saar, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian Ukena, MD</last_name>
    <phone>004968411615912</phone>
    <email>christian.ukena@uks.eu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valerie Pavlicek, MD</last_name>
    <phone>004968411615912</phone>
    <email>valerie.pavlicek@uks.eu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <state>Saarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Ukena, MD</last_name>
      <phone>004968411615912</phone>
      <email>christian.ukena@uks.eu</email>
    </contact>
    <contact_backup>
      <last_name>Valerie Pavlicek, MD</last_name>
      <phone>004968411615912</phone>
      <email>valerie.pavlicek@uks.eu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Gaede L, Kim WK, Liebetrau C, Dörr O, Sperzel J, Blumenstein J, Berkowitsch A, Walther T, Hamm C, Elsässer A, Nef H, Möllmann H. Pacemaker implantation after TAVI: predictors of AV block persistence. Clin Res Cardiol. 2018 Jan;107(1):60-69. doi: 10.1007/s00392-017-1158-2. Epub 2017 Sep 29.</citation>
    <PMID>28963581</PMID>
  </reference>
  <reference>
    <citation>Nazif TM, Williams MR, Hahn RT, Kapadia S, Babaliaros V, Rodés-Cabau J, Szeto WY, Jilaihawi H, Fearon WF, Dvir D, Dewey TM, Makkar RR, Xu K, Dizon JM, Smith CR, Leon MB, Kodali SK. Clinical implications of new-onset left bundle branch block after transcatheter aortic valve replacement: analysis of the PARTNER experience. Eur Heart J. 2014 Jun 21;35(24):1599-607. doi: 10.1093/eurheartj/eht376. Epub 2013 Oct 30.</citation>
    <PMID>24179072</PMID>
  </reference>
  <reference>
    <citation>Urena M, Mok M, Serra V, Dumont E, Nombela-Franco L, DeLarochellière R, Doyle D, Igual A, Larose E, Amat-Santos I, Côté M, Cuéllar H, Pibarot P, de Jaegere P, Philippon F, Garcia del Blanco B, Rodés-Cabau J. Predictive factors and long-term clinical consequences of persistent left bundle branch block following transcatheter aortic valve implantation with a balloon-expandable valve. J Am Coll Cardiol. 2012 Oct 30;60(18):1743-52. doi: 10.1016/j.jacc.2012.07.035. Epub 2012 Oct 3.</citation>
    <PMID>23040577</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 12, 2019</study_first_submitted>
  <study_first_submitted_qc>October 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2019</study_first_posted>
  <last_update_submitted>October 19, 2019</last_update_submitted>
  <last_update_submitted_qc>October 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Saarland</investigator_affiliation>
    <investigator_full_name>Christian Ukena</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Transcatheter valve replacement</keyword>
  <keyword>Infranodal conduction time</keyword>
  <keyword>High-degree AV block</keyword>
  <keyword>Left Bundle-Branch Block</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Bundle-Branch Block</mesh_term>
    <mesh_term>Heart Block</mesh_term>
    <mesh_term>Atrioventricular Block</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

